Category: 53788-12-8

On January 25, 2000, Folkman, Moses J.; Ingber, Donald; Fujita, Takeshi published a patent.Application of 53788-12-8 The title of the patent was Preparation of O-substituted fumagillol derivatives with angiogenesis inhibitory activity. And the patent contained the following:

This invention relates to the preparation and use of O-substituted fumagillol derivatives of formula I [R1 = (substituted) 2-methyl-1-propenyl, (substituted) isobutyl; R2 = alkanoyl, aroyl, aromatic heterocycle-carbonyl, carbamoyl, alkyl, alkylsulfonyl, alkoxycarbonyl, etc.], or salts thereof preferably, O-(N-chloroacetylcarbamoyl)fumagillol, O-(N-chloroacetylcarbamoyl)dihydrofumagillol or O-(N-chloroacetylcarbamoyl)-6’b-hydroxyfumagillol, which have angiogenesis inhibitory activity, in the treatment and prevention of various diseases caused or advanced by abnormally hyperactive angiogenesis, especially various inflammatory diseases (rheumatism, psoriasis, etc.), diabetic retinopathy and cancer and other angiogenesis-dependent tumors, especially Kaposi’s sarcoma, breast cancer, colon cancer. Thus, II (AGM-1470) was prepared from fumagillol and chloroacetyl isocyanate in 71% yield. The T/C ratio of II in the B16 mouse melanoma model was 0.47 after 2 wk and 0.20 after 3 wk. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Application of 53788-12-8

The Article related to fumagillol derivative preparation angiogenesis inhibitor, kaposi sarcoma treatment fumagillol derivative preparation, breast cancer treatment fumagillol derivative preparation, antitumor fumagillol derivative preparation and other aspects.Application of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 18, 1975, there was a patent about cycloaddition reaction.Recommanded Product: 53788-12-8 The title of the patent was p-Dithiino[2,3-c]pyrroles. And the patent contained the following:

Dithiinopyrroles I (R = OH, OMe, R1 = H; R = Me, R1 = H, Me, Cl, OMe; R = H, R1 = Cl, Me, OMe) were prepared by treating the 2-aminonaphthyridines with 5,6-dihydro-1,4-dithiin-2,3-dicarboxylic anhydride, chlorinating when R1 = OH, reducing the dithiinopyrroledione to the monohydroxy derivative, and treating the latter with chlorocarbonylpiperazines. II (R2 = Et, CHMe2, allyl, CH2CH2OH) were similarly prepared The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Recommanded Product: 53788-12-8

The Article related to dithiinopyrrolol piperazinecarboxylate naphthyridinyl pyridinyl, piperazinecarboxylate naphthyridinyldithiinopyrrolyl, pyridinyldithiinopyrrolyl piperazinecarboxylate, aminonaphthyridine dithiindicarboxylate condensation and other aspects.Recommanded Product: 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 16, 2021, Ewin, Richard Andrew; Cox, Mark R.; Hot, Imelda; Bedore, Matthew W.; Respondek, Tomasz; Sheehan, Susan M.K. published a patent.Recommanded Product: 53788-12-8 The title of the patent was Preparation of heteroaryl azalide glycosides as immunomodulators. And the patent contained the following:

Defined herein are immunomodulating heteroaryl azalide glycosides I, stereoisomers thereof, and pharmaceutically acceptable salts thereof; wherein W is H, sugar residue; RingC is Ph, naphthyl, 5-6 membered monocyclic heteroaryl ring or 9-11 membered fused heteroaryl ring; R1 is substituted benzyl, CH2-heteroaryl; R2 is H, alkyl, acyl, substituted amide, alkylaryl, alkyl-heterocycle; R3 is alkyl, alkoxy, haloalkyl, haloalkoxy, alkyl-cycloalkyl, halogen, substituted amine, substituted amide, substituted sulfoxide, nitro, oxo, cyano, -C(O)H, acyl, carboxylate, oxo-carboxylate, OH, heterocyclic, heteroaryl; n is an integer 0-3; and pharmaceutically acceptable salts thereof; and compositions comprising said compounds Thus, heteroaryl azalide glycoside II was prepared The invention also includes methods for treating an inflammatory and/or immunol. disease or disorder in an animal by administering a therapeutically effective amount of compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compounds to prepare a medicament for treating an inflammatory and/or immunol. disease or disorder in an animal. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Recommanded Product: 53788-12-8

The Article related to polonovski demethylation aminoglycoside preparation human antiinflammatory, il1 cd163 tnf nfkb azithromycin macrolide aminoglycoside preparation human, immunomodulating hetero aryl tlr4 toll like receptor antiinflammatory and other aspects.Recommanded Product: 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics